Risk factors for postdischarge VTE include history of VTE, peak D-dimer >3 \u00b5g\/mL, predischarge CRP >10 mg\/dL<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 8, 2021 (HealthDay News) — For patients hospitalized with COVID-19, risk factors for postdischarge venous thromboembolism (VTE) include history of VTE, peak D-dimer level greater than 3 \u00c2\u00b5g\/mL, and predischarge C-reactive protein level greater than 10 mg\/dL, according to a study published online Nov. 22 in JAMA Network Open<\/em>.<\/p>\n Pin Li, Ph.D., from Henry Ford Health System in Detroit, and colleagues quantified the rate of and examined risk factors for postdischarge arterial and venous thromboembolism in a cohort study of 2,832 adult patients hospitalized with COVID-19.<\/p>\n The researchers found that 36 patients (1.3 percent) had postdischarge venous thromboembolic events and there were 15 (0.5 percent) postdischarge arterial thromboembolic events. There was a decrease in the risk for VTE with time, with a median time to event of 16 days. No change was seen in the risk for arterial thromboembolism with time, with a median time to event of 37 days. The likelihood of experiencing VTE after discharge was increased for patients with a history of VTE, peak D-dimer level greater than 3 \u00c2\u00b5g\/mL, and predischarge C-reactive protein level greater than 10 mg\/dL (odds ratios, 3.24, 3.76, and 3.02, respectively). The incidence of VTE was reduced in association with prescriptions for therapeutic anticoagulation at discharge (odds ratio, 0.18).<\/p>\n “We propose that any patients with these risk factors be considered for postdischarge therapeutic anticoagulation if their bleeding risk is low,” the authors write.<\/p>\n One author disclosed financial ties to the pharmaceutical industry.<\/p>\n